DAX22.837 +1,5%ESt505.225 +1,3%Top 10 Crypto12,60 ±0,0%Dow40.753 +0,2%Nas17.711 +1,5%Bitcoin85.086 -0,4%Euro1,1325 +0,3%Öl62,15 +0,5%Gold3.258 +0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Microsoft 870747 Amazon 906866 Rheinmetall 703000 Apple 865985 Tesla A1CX3T Meta Platforms (ex Facebook) A1JWVX Palantir A2QA4J BASF BASF11 Microstrategy 722713 RENK RENK73 Novo Nordisk A3EU6F Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX im Plus -- Asiens Börsen mehrheitlich in Grün -- Amazon verdient mehr als erwartet -- Apple, Airbus, Mercedes-Benz, BigBear.ai im Fokus
Top News
Reduce für BASF-Aktie nach Baader Bank-Analyse Reduce für BASF-Aktie nach Baader Bank-Analyse
Shell-Aktie höher: Rückkauf gestartet Shell-Aktie höher: Rückkauf gestartet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Aurinia Pharmaceuticals Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
7,16 EUR -0,07 EUR -0,94 %
STU
8,20 USD -0,03 USD -0,36 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.989,84 Mio. EUR

KGV228,50Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W7D4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA05156V1022

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAUPH

Aurinia Pharmaceuticals Aktien News

DatumMeistgelesen
BusinesswireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS? (voclosporin) for Patients with Lupus Nephritis at ACR 2023
BusinesswireAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS? for Managing Lupus Nephritis
BusinesswireAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
BusinesswireAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
BusinesswireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
BusinesswireAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
BusinesswireAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
BusinesswireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
BusinesswireAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
BusinesswireAurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
BusinesswireAurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
BusinesswireLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
BusinesswireAurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
BusinesswireAurinia Announces 2023 Annual General Meeting Results
BusinesswireAurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
BusinesswireAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
BusinesswireISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual General Meeting
BusinesswireAurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
BusinesswireGlass Lewis Recommends Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual Meeting
BusinesswireToni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
BusinesswireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
BusinesswireAurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
BusinesswireAurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireAurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
BusinesswireAurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
BusinesswireAurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireAurinia Announces PTAB Has Terminated Inter Partes Review
BusinesswireAurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
BusinesswireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
BusinesswireAurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireAurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireAurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
BusinesswireAurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
BusinesswireAurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
BusinesswireAurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
Wer­bung

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals News: auf dieser Seite finden Sie alle Aurinia Pharmaceuticals News und Nachrichten zur Aurinia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Aurinia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Aurinia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.